In a remarkable medical breakthrough, a long - acting HIV prevention drug has demonstrated astonishing results in clinical trials. The drug, named lenacapavir, offers a revolutionary approach to HIV prevention, with the potential to significantly alter the global fight against the disease.
In June, a large - scale trial in Africa involving over 2,000 women using this therapy reported a staggering outcome: not a single participant in the lenacapavir group became infected with HIV. This result was in stark contrast to the two control groups, both of which were on daily oral medications. Three months later, another trial spanning four continents further validated these findings. Among more than 2,000 participants in this second trial, only two cases of HIV infection were recorded. The prevention efficiency of lenacapavir was still higher than that of the control groups.
Lenacapavir works through a novel mechanism of action. Unlike traditional anti - HIV drugs, it targets the virus's capsid protein. By doing so, it can prevent the virus from interacting with cells and also stops it from entering the cell nucleus. An added advantage is its long - lasting effect. Once administered, the drug can continuously exert its protective function in the body for up to six months. This long - acting feature could potentially improve patient compliance and offer a more convenient and effective way to prevent HIV infection, especially in regions where daily medication adherence is a challenge.
